259 related articles for article (PubMed ID: 17669573)
1. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
4. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
5. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
6. Ziprasidone and cognition: the evolving story.
Harvey PD
J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.
Ritsner MS; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1442-52. PubMed ID: 16842897
[TBL] [Abstract][Full Text] [Related]
9. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.
Endicott J; Paulsson B; Gustafsson U; Schiöler H; Hassan M
J Affect Disord; 2008 Dec; 111(2-3):306-19. PubMed ID: 18774180
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
Mencacci C;
Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
[TBL] [Abstract][Full Text] [Related]
16. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Kohen I; Preval H; Southard R; Francis A
Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
[TBL] [Abstract][Full Text] [Related]
18. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Montes JM; Rodriguez JL; Balbo E; Sopelana P; Martin E; Soto JA; Delgado JF; Diez T; Villardaga I
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):383-8. PubMed ID: 17129654
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]